{"id":119192,"date":"2025-11-06T19:58:09","date_gmt":"2025-11-06T19:58:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/119192\/"},"modified":"2025-11-06T19:58:09","modified_gmt":"2025-11-06T19:58:09","slug":"new-fda-priority-review-vouchers-go-to-lilly-novo-vertex","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/119192\/","title":{"rendered":"New FDA priority review vouchers go to Lilly, Novo, Vertex"},"content":{"rendered":"

WASHINGTON \u2014\u00a0The Food and Drug Administration on Thursday announced the second batch of companies being granted a \u201cCommissioner\u2019s National Priority Voucher,\u201d a ticket to speedier reviews of drug candidates aligned with U.S. priorities.\u00a0<\/p>\n

The announcement came as the Trump administration unveiled agreements<\/a> with Eli Lilly and Novo Nordisk to reduce the prices of popular weight loss drugs \u2014\u00a0part of a broader effort to show its interest in delivering medications to Americans faster, and at cheaper prices, than in the past.\u00a0<\/p>\n

In return for dropping prices, Novo and Lilly each received a priority review voucher, which guarantees a regulatory decision within one to two months. Those vouchers will be used for an oral version of Novo\u2019s weight loss drug Wegovy, which is already under FDA review<\/a>, and Lilly\u2019s orforglipron, an oral weight loss drug based on a different molecule<\/a> than its approved therapy Zepbound.\u00a0\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"WASHINGTON \u2014\u00a0The Food and Drug Administration on Thursday announced the second batch of companies being granted a \u201cCommissioner\u2019s…\n","protected":false},"author":2,"featured_media":87383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[304,6844,1143,163,85,46,482,7299,15830],"class_list":{"0":"post-119192","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-biotechnology","9":"tag-drug-development","10":"tag-fda","11":"tag-health","12":"tag-il","13":"tag-israel","14":"tag-medication","15":"tag-pharmaceuticals","16":"tag-stat"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/119192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=119192"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/119192\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/87383"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=119192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=119192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=119192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}